Homocystinuria is More Common Than We Thought, It’s Just Not Detected Well in NBS
https://pixabay.com/en/baby-care-child-cute-hand-face-20339/

Homocystinuria is More Common Than We Thought, It’s Just Not Detected Well in NBS

Most patients diagnosed with Homocystinuria (HCU), a rare metabolic disorder, don't receive their diagnosis until later in life. Scientists were at a loss for why patients with phenylketonuria (PKU), a similar…

Continue Reading Homocystinuria is More Common Than We Thought, It’s Just Not Detected Well in NBS
The Patriots Raise Awareness for Sickle Cell Anemia and Duchenne Muscular Dystrophy
Source: Pixabay.com

The Patriots Raise Awareness for Sickle Cell Anemia and Duchenne Muscular Dystrophy

This past Sunday, December 2nd, during the Patriot's game against the Minnesota Vikings, 20 players wore customized cleats to spread awareness for various philanthropic causes. This is the third year…

Continue Reading The Patriots Raise Awareness for Sickle Cell Anemia and Duchenne Muscular Dystrophy
International Experts Met with Goal to Improve Care for Chronic Myelomonocytic Leukemia Patients
https://pixabay.com/en/earth-planet-space-satellite-1913747/

International Experts Met with Goal to Improve Care for Chronic Myelomonocytic Leukemia Patients

Chronic myelomonocytic leukemia, or CMML, is a rare condition. However, it has similarities to myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). That being said, it still a unique diagnosis, and…

Continue Reading International Experts Met with Goal to Improve Care for Chronic Myelomonocytic Leukemia Patients
Potential New Treatment for Huntington’s Disease Granted Orphan Drug Designation
Source: Pixabay.com

Potential New Treatment for Huntington’s Disease Granted Orphan Drug Designation

Huntington's Disease is a neurodegenerative condition caused by a genetic mutation. It results in progressive decline of motor skills. It also affects cognitive function. Patients experience decline for 15-20 years…

Continue Reading Potential New Treatment for Huntington’s Disease Granted Orphan Drug Designation

Potential New Treatment for Amyotrophic Lateral Sclerosis which Doesn’t Require Swallowing!

Amyotrophic lateral sclerosis (ALS) is a condition which affects the bodies nerve cells. It's neurodegenerative and progressive, causing the patient muscle weakness and muscle atrophy. It eventually results in paralysis.…

Continue Reading Potential New Treatment for Amyotrophic Lateral Sclerosis which Doesn’t Require Swallowing!
A New Combination of Therapies has Potential to Treat all Mantle Cell Lymphoma Patients
Source: Pixabay.com

A New Combination of Therapies has Potential to Treat all Mantle Cell Lymphoma Patients

Mantle cell lymphoma is caused by a genetic mutation which  produces cancerous white blood cells. Of course, these are the cells which fight infection in a normal body. Therefore in…

Continue Reading A New Combination of Therapies has Potential to Treat all Mantle Cell Lymphoma Patients
New Treatment for Lambert-Eaton Myasthenic Syndrome Approved by FDA!
https://patientworthy.com/wp-content/uploads/2018/11/perspective-175642_1280.png

New Treatment for Lambert-Eaton Myasthenic Syndrome Approved by FDA!

Lambert-Eaton Myasthenic Syndrome (LEMS) is an autoimmune disorder. It's a rare condition characterized by muscle weakness in the limbs. When the muscle weakness includes the respiratory muscles, the disease can…

Continue Reading New Treatment for Lambert-Eaton Myasthenic Syndrome Approved by FDA!
New Approval Gives Juvenile Idiopathic Arthritis Patients More Options
kfuhlert / Pixabay

New Approval Gives Juvenile Idiopathic Arthritis Patients More Options

On November 26, 2018, the FDA approved a new autoinjector for individuals with severe rheumatoid arthritis (RA), giant cell arteritis, and polyarticular or systemic juvenile idiopathic arthritis (aged 2 and older). It's…

Continue Reading New Approval Gives Juvenile Idiopathic Arthritis Patients More Options
Second Ever Cancer Treatment Based on Biomarkers Approved by FDA
Source: Pixabay.com

Second Ever Cancer Treatment Based on Biomarkers Approved by FDA

On November 26, 2018, a new drug was given accelerated approval by the FDA. Not only that, but it was granted orphan drug designation and breakthrough therapy designation. The drug…

Continue Reading Second Ever Cancer Treatment Based on Biomarkers Approved by FDA